A Phase 2 interventional study of Saline placebo and CD388 in Influenza, sponsored by Cidara Therapeutics Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Cidara Therapeutics Inc. (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Influenza, Human with a site in United Kingdom — 8 open to participants now, 13 under way, 4 of them phase 3. Influenza, Human · United Kingdom.
Among the 151 studies in Influenza, Human with a site in United Kingdom, this one is the 96th largest by enrollment of the 123 interventional ones that give a count, is one of 7 that started in 2022, is one of 38 in phase 2, and was the 128th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →8 of the 151 studies in Influenza, Human with a site in United Kingdom are open now. Recruiting first, the newest first:
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Sites in United Kingdom, United States, Argentina and 3 more countries
Ages 12+
Imperial College London · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
Region Örebro County · Sites in United Kingdom, Denmark, Sweden
Ages 18+
Hvivo · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
AstraZeneca · Sites in United Kingdom, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 43 · Phase 3 21 · Phase 4 16
First in 2003; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 129 across the 123 interventional studies, 574 across the 28 observational. Of the 131 that completed or were terminated, 47 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
90 of 151 have an industry lead sponsor. The 10 most frequent:
This study is registered under Cidara Therapeutics Inc., one of the names counted as Merck & Co., Inc. Under that name alone:
Cidara Therapeutics Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Merck & Co., Inc has 7 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
5 of the studies in Influenza, Human with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496450Phase 3ModernaTX, Inc.A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | 2027-01-28 |
| NCT07159763Phase 3Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | 2027-07-02 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07503405Traws Pharma, Inc.Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model | 2026-11 |
| NCT07225959Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07) | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 151 studies in Influenza, Human with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the preventative antiviral activity of CD388, as compared to saline placebo, when administered as a single dose to healthy adult participants in a human viral challenge model of influenza.
This is a single-center, randomized, double-blind, placebo-controlled, proof-of-concept study in healthy adult male and female participants 18 to 55 years of age, inclusive. The primary goal of this Phase 2a study is to assess the prophylactic antiviral activity against influenza, safety, tolerability, and pharmacokinetics (PK) of CD388 via a human viral challenge (HVC) model, and to explore the impact of dose levels on efficacy. Each participant will receive a single administration of CD388 or placebo; multiple dose levels of CD388 may be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following criteria are applicable to female participants participating in the study.
Females of non-childbearing potential:
The following criteria apply to female and male participants:
Female participants of childbearing potential must use 1 form of highly effective contraception. Hormonal methods must be in place from at least 2 weeks prior to the first study visit. The contraception use must continue until 5 effective half-lives (205 days) after the last dose of medicinal product (IMP). Highly effective contraception is as described below:
Established use of hormonal methods of contraception described below (for a minimum of 30 days prior to the first study visit). When hormonal methods of contraception are used, male partners are required to use a condom with a spermicide:
a) combined (estrogen- and progestogen containing) hormonal contraception associated with inhibition of ovulation:
b) progestogen-only hormonal contraception associated with inhibition of ovulation:
Male participants must agree to the contraceptive requirements below at entry to quarantine and continuing until 5 effective half-lives (205 days) after the last dose of IMP.
Exclusion Criteria:
Any history or evidence of any or currently active cardiovascular, respiratory, dermatological, gastrointestinal, endocrinological, hematological, hepatic, immunological (including ), metabolic, urological, renal, neurological, or psychiatric disease and/or other major disease that, in the opinion of the PI/investigator may interfere with a participant completing the study and necessary investigations. The following conditions apply:
Females who:
. .
. .
. .
Use or anticipated use during the conduct of the study of concomitant medications (prescription and/or non-prescription), including vitamins or herbal and dietary supplements within the specified windows, unless in the opinion of the study physician/PI, the medication will not interfere with the study procedures or compromise participant safety. Specifically, the following are excluded:
. .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Cohort 1, up to 30 participants will be randomized to receive a single dose of placebo, administered by subcutaneous (SQ) injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 1, to receive a single dose of placebo by SQ injection prior to viral challenge.
Drug: Saline placebo
In Cohort 1, up to 30 participants will be randomized to receive a single dose of 150 milligrams (mg) CD388, administered by SQ injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 2, to receive a single dose of 150 mg CD388 by SQ injection prior to viral challenge.
Combination Product: CD388
In Cohort 1, up to 30 participants will be randomized to receive a single dose of 50 mg CD388, administered by SQ injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 3, to receive a single dose of 50mg CD388 by SQ injection prior to viral challenge.
Combination Product: CD388
Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 4, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.
Combination Product: CD388
Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 5, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.
Combination Product: CD388
Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 6, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.
Combination Product: CD388
Sterile normal saline for injection
CD388 liquid for injection
Mean Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge
Evaluation of the prophylactic effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) on nasal samples starting 1 day post viral challenge.
Time frame: Day 1 (evening [pm]); Days 2, 3, 4, 5, 6, and 7 (morning [am] and pm); Day 8 (am)
Median Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge
Evaluation of the prophylactic effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) on nasal samples starting 1 day post viral challenge.
Time frame: Day 1 (evening [pm]); Days 2, 3, 4, 5, 6, and 7 (morning [am] and pm); Day 8 (am)
Mean Peak Viral Load by qRT-PCR After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantifiable qRT-PCR measurements in nasal samples starting 1 day post viral challenge.
Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Median Peak Viral Load by qRT-PCR After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantifiable qRT-PCR measurements in nasal samples starting 1 day post viral challenge.
Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Time to Confirmed Negative Test by qRT-PCR After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the time (in hours, as estimated using the Kaplan-Meier method) to confirmed negative test for influenza as determined by quantifiable qRT-PCR measurements in nasal samples starting 1 day post viral challenge.
Time frame: From Day 1 (pm) until the first confirmed undetectable assessment after peak measurement, assessed up to Day 8 (am)
Mean Area Under the Viral Load-Time Curve (VL-AUC) by Viral Culture After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by viral culture on nasal samples starting 1 day post viral challenge.
Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Median Area Under the Viral Load-Time Curve (VL-AUC) by Viral Culture After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by viral culture on nasal samples starting 1 day post viral challenge.
Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Mean Peak Viral Load by Viral Culture After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantitative viral culture measurements in nasal samples starting 1 day post viral challenge.
Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Median Peak Viral Load by Viral Culture After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantitative viral culture measurements in nasal samples starting 1 day post viral challenge.
Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Time to Confirmed Negative Test by Viral Culture After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the time (in hours, as estimated using the Kaplan-Meier method) to confirmed negative test for influenza as determined by quantifiable viral culture measurements in nasal samples starting 1 day post viral challenge.
Time frame: From Day 1 (pm) until the first confirmed undetectable assessment after peak measurement, assessed up to Day 8 (am)
Mean Area Under the Total Clinical Symptoms Score-Time Curve (TSS-AUC) After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on TSS-AUC as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.
Time frame: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Median Area Under the Total Clinical Symptoms Score-Time Curve (TSS-AUC) After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on TSS-AUC as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.
Time frame: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Mean Peak Total Clinical Symptoms Score (TSS) After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) TSS score as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.
Time frame: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Median Peak Total Clinical Symptoms Score (TSS) After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) TSS score as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.
Time frame: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Mean Individual Peak Daily Total Clinical Symptoms Score After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) daily symptom score (i.e., individual maximum daily sum of symptom score) as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment as the sum of the scores given to the 13 symptoms, giving possible TSS values from 0 to 39.
Time frame: From Day 1 up to Day 8
Median Individual Peak Daily Total Clinical Symptoms Score After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) daily symptom score (i.e., individual maximum daily sum of symptom score) as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment as the sum of the scores given to the 13 symptoms, giving possible TSS values from 0 to 39.
Time frame: From Day 1 up to Day 8
Time to Symptom Resolution After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the time (in hours, as estimated using the Kaplan-Meier method) to symptom resolution (i.e., first time with Total Symptom Score \[TSS\] equal to the TSS at baseline after which no further increase above the baseline TSS was observed) as measured by graded daily symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. An individual TSS is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.
Time frame: Starting Day 1, from the time of peak daily symptom score until the time of returning to baseline score, up to Day 8
Number of Participants With qRT-PCR-Confirmed Influenza Infection After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the number of participants with qRT-PCR-confirmed influenza infection, defined as 2 quantifiable (≥ lower limit of quantification \[LLOQ\]) qRT-PCR measurements (reported on 2 or more independent nasal samples over 2 days), starting 1 day post viral challenge.
Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Percentage of Participants With qRT-PCR-Confirmed Influenza Infection After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with qRT-PCR-confirmed influenza infection, defined as 2 quantifiable (≥ lower limit of quantification \[LLOQ\]) qRT-PCR measurements (reported on 2 or more independent nasal samples over 2 days), starting 1 day post viral challenge.
Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Number of Participants With at Least One Positive Quantitative (≥LLOQ) Cell Culture After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the number of participants with at least 1 positive quantitative (≥LLOQ) cell culture measurement in nasal samples starting 1 day post viral challenge.
Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Percentage of Participants With at Least One Positive Quantitative (≥LLOQ) Cell Culture After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with at least 1 positive quantitative (≥LLOQ) cell culture measurement in nasal samples starting 1 day post viral challenge.
Time frame: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am)
Number of Participants With qRT-PCR-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the number of participants with qRT-PCR-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.
Time frame: • For qRT-PCR measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For TSS measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Percentage of Participants With qRT-PCR-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with qRT-PCR-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.
Time frame: • For qRT-PCR measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For TSS measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Number of Participants With qRT-PCR-Confirmed Moderately Severe Symptomatic Influenza Infection After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the number of participants with qRT-PCR-confirmed moderately severe symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * One or more symptoms of grade ≥2 at a single time point (i.e., on any individual symptom card), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.
Time frame: • For qRT-PCR measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For symptom scoring measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Percentage of Participants With qRT-PCR-Confirmed Moderately Severe Symptomatic Influenza Infection After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with qRT-PCR-confirmed moderately severe symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * One or more symptoms of grade ≥2 at a single time point (i.e., on any individual symptom card), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.
Time frame: • For qRT-PCR measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For symptom scoring measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Number of Participants With Culture Lab-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the number of participants with culture laboratory-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * Lab-confirmed culturable influenza infection (1 quantifiable \[≥LLOQ\] cell culture measurement in nasal samples), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.
Time frame: • For viral culture measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For TSS measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Percentage of Participants With Culture Lab-Confirmed Symptomatic Influenza Infection After Influenza Viral Challenge
Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with culture laboratory-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * Lab-confirmed culturable influenza infection (1 quantifiable \[≥LLOQ\] cell culture measurement in nasal samples), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.
Time frame: • For viral culture measurements: Day 1 (pm); Days 2, 3, 4, 5, 6, and 7 (am and pm); Day 8 (am) • For TSS measurements: Three (3) times per day, at the same time each day (±1 hour), on Days 1, 2, 3, 4, 5, 6, and 7; and on Day 8 (am only)
Occurrence of Solicited Adverse Events (AEs) From Subcutaneous (SQ) Dosing up to Viral Challenge - Number of Participants
Evaluation of the occurrence of solicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of inoculation with the influenza challenge virus, based on the number of participants reporting any solicited AE. Solicited AEs are those predefined events relating to reactogenicity (pain, tenderness, erythema/redness, induration/swelling) for which participants were specifically questioned and which were noted by participants in a participant diary.
Time frame: From Day -5 (dosing) up to Day 0 (viral challenge)
Occurrence of Solicited Adverse Events (AEs) From Subcutaneous (SQ) Dosing up to Viral Challenge - Number of Events
Evaluation of the occurrence of solicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of inoculation with the influenza challenge virus, based on the number of events reported. Solicited AEs are those predefined events relating to reactogenicity (pain, tenderness, erythema/redness, induration/swelling) for which participants were specifically questioned and which were noted by participants in a participant diary.
Time frame: From Day -5 (dosing) up to Day 0 (viral challenge)
Occurrence of Unsolicited AEs From SQ Dosing up to Day 28 Follow-up Visit - Number of Participants
Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 28 follow-up visit, based on the number of participants for whom any AE is observed. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 1 (from Day -5 dosing to just before challenge virus inoculation on Day 0) * Period 2 (from Day 0 challenge virus inoculation to actual discharge from the quarantine unit \[as scheduled on Day 8 or later at PI's decision\]) * Period 3 (from actual discharge from the quarantine unit to Day 28 (±3 days)
Time frame: From Day -5 (dosing) up to Day 28 (±3 days)
Occurrence of Unsolicited AEs From SQ Dosing up to Day 28 Follow-up Visit - Number of Events
Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 28 follow-up visit, based on the number of events reported. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 1 (from Day -5 dosing to just before challenge virus inoculation on Day 0) * Period 2 (from Day 0 challenge virus inoculation to actual discharge from the quarantine unit \[as scheduled on Day 8 or later at PI's decision\]) * Period 3 (from actual discharge from the quarantine unit to Day 28 (±3 days)
Time frame: From Day -5 (dosing) up to Day 28 (±3 days)
Occurrence of Unsolicited AEs From SQ Dosing up to the Final Follow-up Visit - Number of Participants
Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 180 final follow-up visit, based on the number of participants for whom any AE was observed. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 3 (from actual discharge from the quarantine unit to Day 28 \[±3 days\]) * Period 4 (from Day 28\[±3 days\] to the final follow-up visit \[Day 180 ±14 days\]) * Across All Periods (from Day -5 dosing to the final follow-up visit \[Day 180 ±14 days\])
Time frame: From Day -5 (dosing) up to Day 180 (±14 days)
Occurrence of Unsolicited AEs From SQ Dosing up to the Final Follow-up Visit - Number of Events
Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 180 final follow-up visit, based on the number of events reported. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 3 (from actual discharge from the quarantine unit to Day 28 \[±3 days\]) * Period 4 (from Day 28\[±3 days\] to the final follow-up visit \[Day 180 ±14 days\]) * Across All Periods (from Day -5 dosing to the final follow-up visit \[Day 180 ±14 days\])
Time frame: From Day -5 (dosing) up to Day 180 (±14 days)
Up to 168 participants in up to 2 cohorts were planned for enrollment in the study. Due to low participant eligibility, the randomization schedule was changed in Cohort 1 after the first quarantine group to only randomize participants to the 150 mg CD388 and placebo arms. With only 2 participants in the 50 mg CD388 arm, safety and demographic data only have been reported. Based on data from the planned interim analysis of Cohort 1, a decision was made to not proceed with Cohort 2.
| Milestone | Placebo | 50 mg CD388 | 150 mg CD388 |
|---|---|---|---|
| Started | 29 | 2 | 28 |
| Completed | 27 | 2 | 28 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
Evaluation of the prophylactic effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) on nasal samples starting 1 day post viral challenge.
| log[10] copies/milliliter (mL)*hour | Placebo | 150 mg CD388 |
|---|---|---|
| Mean Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge | 16.09 ± 11.86 | 10.70 ± 8.01 |
Evaluation of the prophylactic effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) on nasal samples starting 1 day post viral challenge.
| log[10] copies/mL*hour | Placebo | 150 mg CD388 |
|---|---|---|
| Median Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge | 8.52 (6.4 to 39.8) | 6.40 (6.4 to 29.9) |
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantifiable qRT-PCR measurements in nasal samples starting 1 day post viral challenge.
| log[10] copies/mL | Placebo | 150 mg CD388 |
|---|---|---|
| Mean Peak Viral Load by qRT-PCR After Influenza Viral Challenge | 4.28 ± 2.94 | 2.84 ± 2.40 |
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantifiable qRT-PCR measurements in nasal samples starting 1 day post viral challenge.
| log[10] copies/mL | Placebo | 150 mg CD388 |
|---|---|---|
| Median Peak Viral Load by qRT-PCR After Influenza Viral Challenge | 3.79 (1.0 to 8.5) | 0.97 (0.9 to 7.5) |
Evaluation of the effect of CD388, when compared to placebo, on the time (in hours, as estimated using the Kaplan-Meier method) to confirmed negative test for influenza as determined by quantifiable qRT-PCR measurements in nasal samples starting 1 day post viral challenge.
| hours | Placebo | 150 mg CD388 |
|---|---|---|
| 25th Percentile | 61.9 (14.7 to 120.3) | 66.7 (24.3 to 72.4) |
| Median | 134.1 (61.9 to NA) | 79.4 (24.4 to 143.1) |
| 75th Percentile | 158.3 (134.1 to NA) | 131.7 (72.4 to NA) |
Evaluation of the effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by viral culture on nasal samples starting 1 day post viral challenge.
| log[10] copies/mL*hour | Placebo | 150 mg CD388 |
|---|---|---|
| Mean Area Under the Viral Load-Time Curve (VL-AUC) by Viral Culture After Influenza Viral Challenge | 5.82 ± 3.70 | 3.95 ± 1.57 |
Evaluation of the effect of CD388, when compared to placebo, on VL-AUC of influenza challenge virus as determined by viral culture on nasal samples starting 1 day post viral challenge.
| log[10] copies/mL*hour | Placebo | 150 mg CD388 |
|---|---|---|
| Median Area Under the Viral Load-Time Curve (VL-AUC) by Viral Culture After Influenza Viral Challenge | 3.29 (3.2 to 14.4) | 3.29 (3.2 to 9.7) |
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantitative viral culture measurements in nasal samples starting 1 day post viral challenge.
| log[10] copies/mL | Placebo | 150 mg CD388 |
|---|---|---|
| Mean Peak Viral Load by Viral Culture After Influenza Viral Challenge | 2.13 ± 2.10 | 1.07 ± 1.18 |
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) viral load of influenza as determined by quantitative viral culture measurements in nasal samples starting 1 day post viral challenge.
| log[10] copies/mL | Placebo | 150 mg CD388 |
|---|---|---|
| Median Peak Viral Load by Viral Culture After Influenza Viral Challenge | 0.50 (0.5 to 5.5) | 0.50 (0.5 to 4.5) |
Evaluation of the effect of CD388, when compared to placebo, on the time (in hours, as estimated using the Kaplan-Meier method) to confirmed negative test for influenza as determined by quantifiable viral culture measurements in nasal samples starting 1 day post viral challenge.
| hours | Placebo | 150 mg CD388 |
|---|---|---|
| 25th Percentile | 71.4 (47.2 to 85.9) | 62.3 (24.3 to 85.9) |
| Median | 85.9 (47.5 to 110.1) | 78.7 (24.3 to NA) |
| 75th Percentile | 110.1 (85.9 to NA) | 86.0 (62.3 to NA) |
Evaluation of the effect of CD388, when compared to placebo, on TSS-AUC as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.
| TSS points*day | Placebo | 150 mg CD388 |
|---|---|---|
| Mean Area Under the Total Clinical Symptoms Score-Time Curve (TSS-AUC) After Influenza Viral Challenge | 7.66 ± 14.13 | 2.22 ± 4.86 |
Evaluation of the effect of CD388, when compared to placebo, on TSS-AUC as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.
| TSS points*day | Placebo | 150 mg CD388 |
|---|---|---|
| Median Area Under the Total Clinical Symptoms Score-Time Curve (TSS-AUC) After Influenza Viral Challenge | 0.45 (0.0 to 48.3) | 0.86 (0.0 to 25.2) |
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) TSS score as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.
| total symptom score | Placebo | 150 mg CD388 |
|---|---|---|
| Mean Peak Total Clinical Symptoms Score (TSS) After Influenza Viral Challenge | 3.54 ± 5.34 | 1.79 ± 3.12 |
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) TSS score as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.
| total symptom score | Placebo | 150 mg CD388 |
|---|---|---|
| Median Peak Total Clinical Symptoms Score (TSS) After Influenza Viral Challenge | 1.00 (0.0 to 21.0) | 1.00 (0.0 to 16.0) |
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) daily symptom score (i.e., individual maximum daily sum of symptom score) as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment as the sum of the scores given to the 13 symptoms, giving possible TSS values from 0 to 39.
| total symptom score | Placebo | 150 mg CD388 |
|---|---|---|
| Quarantine Day 1 | 0.64 ± 1.50 | 0.46 ± 0.84 |
| Quarantine Day 2 | 2.29 ± 4.60 | 0.75 ± 2.12 |
| Quarantine Day 3 | 2.79 ± 5.10 | 1.25 ± 3.15 |
| Quarantine Day 4 | 2.11 ± 3.83 | 0.82 ± 1.85 |
| Quarantine Day 5 | 1.07 ± 2.12 | 0.36 ± 0.87 |
| Quarantine Day 6 | 0.79 ± 1.91 | 0.39 ± 0.69 |
| Quarantine Day 7 | 0.43 ± 1.53 | 0.07 ± 0.26 |
| Quarantine Day 8 Discharge | 0.15 ± 0.60 | 0.11 ± 0.42 |
Evaluation of the effect of CD388, when compared to placebo, on the peak (i.e., maximum) daily symptom score (i.e., individual maximum daily sum of symptom score) as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. At each assessment, the participant provides scores from 0 to 3 for a list of 13 symptoms (runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle and/or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze). Grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with normal daily activities; grade 3: quite bothersome most or all the time and stops participation in activities. An individual Total Symptom Score (TSS) is derived at each assessment as the sum of the scores given to the 13 symptoms, giving possible TSS values from 0 to 39.
| total symptom score | Placebo | 150 mg CD388 |
|---|---|---|
| Quarantine Day 1 | 0.00 (0.0 to 7.0) | 0.00 (0.0 to 3.0) |
| Quarantine Day 2 | 0.00 (0.0 to 17.0) | 0.00 (0.0 to 11.0) |
| Quarantine Day 3 | 0.00 (0.0 to 21.0) | 0.00 (0.0 to 16.0) |
| Quarantine Day 4 | 0.00 (0.0 to 14.0) | 0.00 (0.0 to 8.0) |
| Quarantine Day 5 | 0.00 (0.0 to 8.0) | 0.00 (0.0 to 4.0) |
| Quarantine Day 6 | 0.00 (0.0 to 9.0) | 0.00 (0.0 to 2.0) |
| Quarantine Day 7 | 0.00 (0.0 to 8.0) | 0.00 (0.0 to 1.0) |
| Quarantine Day 8 Discharge | 0.00 (0.0 to 3.0) | 0.00 (0.0 to 2.0) |
Evaluation of the effect of CD388, when compared to placebo, on the time (in hours, as estimated using the Kaplan-Meier method) to symptom resolution (i.e., first time with Total Symptom Score \[TSS\] equal to the TSS at baseline after which no further increase above the baseline TSS was observed) as measured by graded daily symptom scoring system (participant completed symptom diary card) collected 3 times daily starting 1 day post viral challenge. An individual TSS is derived at each assessment of the diary card as the sum of the scores given to the 13 symptoms on that symptom score card, resulting in possible TSS values from 0 to 39.
| hours | Placebo | 150 mg CD388 |
|---|---|---|
| 25th Percentile | 8.4 (6.9 to 31.1) | 23.3 (6.7 to 54.3) |
| Median | 41.5 (8.4 to 72.7) | 74.8 (23.3 to 96.2) |
| 75th Percentile | 78.7 (41.5 to NA) | 133.5 (84.4 to NA) |
Evaluation of the effect of CD388, when compared to placebo, on the number of participants with qRT-PCR-confirmed influenza infection, defined as 2 quantifiable (≥ lower limit of quantification \[LLOQ\]) qRT-PCR measurements (reported on 2 or more independent nasal samples over 2 days), starting 1 day post viral challenge.
| Participants | Placebo | 150 mg CD388 |
|---|---|---|
| No qRT-PCR-confirmed Influenza Infection | 14 | 22 |
| qRT-PCR-confirmed Influenza Infection | 14 | 6 |
Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with qRT-PCR-confirmed influenza infection, defined as 2 quantifiable (≥ lower limit of quantification \[LLOQ\]) qRT-PCR measurements (reported on 2 or more independent nasal samples over 2 days), starting 1 day post viral challenge.
| percentage of participants | Placebo | 150 mg CD388 |
|---|---|---|
| No qRT-PCR-confirmed Influenza Infection | 50.0 (30.6 to 69.4) | 78.6 (59.0 to 91.7) |
| qRT-PCR-confirmed Influenza Infection | 50.0 (30.6 to 69.4) | 21.4 (8.3 to 41.0) |
Evaluation of the effect of CD388, when compared to placebo, on the number of participants with at least 1 positive quantitative (≥LLOQ) cell culture measurement in nasal samples starting 1 day post viral challenge.
| Participants | Placebo | 150 mg CD388 |
|---|---|---|
| No Positive Quantitative (≥LLOQ) Cell Culture | 17 | 22 |
| At Least 1 Positive Quantitative (≥LLOQ) Cell Culture | 11 | 6 |
Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with at least 1 positive quantitative (≥LLOQ) cell culture measurement in nasal samples starting 1 day post viral challenge.
| percentage of participants | Placebo | 150 mg CD388 |
|---|---|---|
| No Positive Quantitative (≥LLOQ) Cell Culture | 60.7 (40.6 to 78.5) | 78.6 (59.0 to 91.7) |
| At Least 1 Positive Quantitative (≥LLOQ) Cell Culture | 39.3 (21.5 to 59.4) | 21.4 (8.3 to 41.0) |
Evaluation of the effect of CD388, when compared to placebo, on the number of participants with qRT-PCR-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.
| Participants | Placebo | 150 mg CD388 |
|---|---|---|
| No qRT-PCR-confirmed Symptomatic Influenza Infection | 19 | 24 |
| qRT-PCR-confirmed Symptomatic Influenza Infection | 9 | 4 |
Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with qRT-PCR-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.
| percentage of participants | Placebo | 150 mg CD388 |
|---|---|---|
| No qRT-PCR-confirmed Symptomatic Influenza Infection | 67.9 (47.6 to 84.1) | 85.7 (67.3 to 96.0) |
| qRT-PCR-confirmed Symptomatic Influenza Infection | 32.1 (15.9 to 52.4) | 14.3 (4.0 to 32.7) |
Evaluation of the effect of CD388, when compared to placebo, on the number of participants with qRT-PCR-confirmed moderately severe symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * One or more symptoms of grade ≥2 at a single time point (i.e., on any individual symptom card), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.
| Participants | Placebo | 150 mg CD388 |
|---|---|---|
| No qRT-PCR-confirmed Moderately Severe Symptomatic Influenza Infection | 21 | 25 |
| qRT-PCR-confirmed Moderately Severe Symptomatic Influenza Infection | 7 | 3 |
Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with qRT-PCR-confirmed moderately severe symptomatic influenza infection starting 1 day post viral challenge, defined as: * RT-PCR-confirmed influenza infection (2 quantifiable \[≥LLOQ\] qRT-PCR measurements \[reported on 2 or more independent nasal samples over 2 days\]), AND * One or more symptoms of grade ≥2 at a single time point (i.e., on any individual symptom card), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.
| percentage of participants | Placebo | 150 mg CD388 |
|---|---|---|
| No qRT-PCR-confirmed Moderately Severe Symptomatic Influenza Infection | 75.0 (55.1 to 89.3) | 89.3 (71.8 to 97.7) |
| qRT-PCR-confirmed Moderately Severe Symptomatic Influenza Infection | 25.0 (10.7 to 44.9) | 10.7 (2.3 to 28.2) |
Evaluation of the effect of CD388, when compared to placebo, on the number of participants with culture laboratory-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * Lab-confirmed culturable influenza infection (1 quantifiable \[≥LLOQ\] cell culture measurement in nasal samples), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.
| Participants | Placebo | 150 mg CD388 |
|---|---|---|
| No Culture Lab-confirmed Symptomatic Influenza Infection | 20 | 24 |
| Culture Lab-confirmed Symptomatic Influenza Infection | 8 | 4 |
Evaluation of the effect of CD388, when compared to placebo, on the percentage of participants with culture laboratory-confirmed symptomatic influenza infection starting 1 day post viral challenge, defined as: * Lab-confirmed culturable influenza infection (1 quantifiable \[≥LLOQ\] cell culture measurement in nasal samples), AND * TSS score ≥2 at any single time point (i.e., any individual symptom diary card for which the sum of symptom scores is ≥2; e.g., at a minimum, ≥1 symptom of grade ≥2, or ≥2 symptoms of grade ≥1), as measured by graded symptom scoring system (participant completed symptom diary card) collected 3 times daily.
| percentage of participants | Placebo | 150 mg CD388 |
|---|---|---|
| No Culture Lab-confirmed Symptomatic Influenza Infection | 71.4 (51.3 to 86.8) | 85.7 (67.3 to 96.0) |
| Culture Lab-confirmed Symptomatic Influenza Infection | 28.6 (13.2 to 48.7) | 14.3 (4.0 to 32.7) |
Evaluation of the occurrence of solicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of inoculation with the influenza challenge virus, based on the number of participants reporting any solicited AE. Solicited AEs are those predefined events relating to reactogenicity (pain, tenderness, erythema/redness, induration/swelling) for which participants were specifically questioned and which were noted by participants in a participant diary.
| Participants | Placebo | 50 mg CD388 | 150 mg CD388 |
|---|---|---|---|
| Occurrence of Solicited Adverse Events (AEs) From Subcutaneous (SQ) Dosing up to Viral Challenge - Number of Participants | 0 | 0 | 1 |
Evaluation of the occurrence of solicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of inoculation with the influenza challenge virus, based on the number of events reported. Solicited AEs are those predefined events relating to reactogenicity (pain, tenderness, erythema/redness, induration/swelling) for which participants were specifically questioned and which were noted by participants in a participant diary.
| events | Placebo | 50 mg CD388 | 150 mg CD388 |
|---|---|---|---|
| Occurrence of Solicited Adverse Events (AEs) From Subcutaneous (SQ) Dosing up to Viral Challenge - Number of Events | 0 | 0 | 1 |
Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 28 follow-up visit, based on the number of participants for whom any AE is observed. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 1 (from Day -5 dosing to just before challenge virus inoculation on Day 0) * Period 2 (from Day 0 challenge virus inoculation to actual discharge from the quarantine unit \[as scheduled on Day 8 or later at PI's decision\]) * Period 3 (from actual discharge from the quarantine unit to Day 28 (±3 days)
| Participants | Placebo | 50 mg CD388 | 150 mg CD388 |
|---|---|---|---|
| Period 1 | 1 | 1 | 0 |
| Periods 1 and 2 | 4 | 1 | 2 |
| Period 2 | 3 | 1 | 2 |
| Periods 2 and 3 | 10 | 1 | 11 |
| Period 3 | 8 | 1 | 9 |
Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 28 follow-up visit, based on the number of events reported. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 1 (from Day -5 dosing to just before challenge virus inoculation on Day 0) * Period 2 (from Day 0 challenge virus inoculation to actual discharge from the quarantine unit \[as scheduled on Day 8 or later at PI's decision\]) * Period 3 (from actual discharge from the quarantine unit to Day 28 (±3 days)
| events | Placebo | 50 mg CD388 | 150 mg CD388 |
|---|---|---|---|
| Period 1 | 1 | 1 | 0 |
| Periods 1 and 2 | 4 | 2 | 2 |
| Period 2 | 3 | 1 | 2 |
| Periods 2 and 3 | 12 | 3 | 13 |
| Period 3 | 9 | 2 | 11 |
Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 180 final follow-up visit, based on the number of participants for whom any AE was observed. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 3 (from actual discharge from the quarantine unit to Day 28 \[±3 days\]) * Period 4 (from Day 28\[±3 days\] to the final follow-up visit \[Day 180 ±14 days\]) * Across All Periods (from Day -5 dosing to the final follow-up visit \[Day 180 ±14 days\])
| Participants | Placebo | 50 mg CD388 | 150 mg CD388 |
|---|---|---|---|
| Period 3 | 8 | 1 | 9 |
| Periods 3 and 4 | 16 | 1 | 19 |
| Period 4 | 9 | 0 | 14 |
| Across All Periods | 19 | 1 | 21 |
Evaluation of the occurrence of unsolicited AEs in participants dosed with CD388, when compared with placebo, from the time of SQ dosing up to the time of the Day 180 final follow-up visit, based on the number of events reported. Unsolicited AEs are any AEs observed by the participant or Principal Investigator (PI)/investigator which are not prelisted on a symptom diary card. Results are categorized by period: * Period 3 (from actual discharge from the quarantine unit to Day 28 \[±3 days\]) * Period 4 (from Day 28\[±3 days\] to the final follow-up visit \[Day 180 ±14 days\]) * Across All Periods (from Day -5 dosing to the final follow-up visit \[Day 180 ±14 days\])
| events | Placebo | 50 mg CD388 | 150 mg CD388 |
|---|---|---|---|
| Period 3 | 9 | 2 | 11 |
| Periods 3 and 4 | 21 | 2 | 32 |
| Period 4 | 12 | 0 | 21 |
| Across All Periods | 25 | 4 | 34 |
Collected over Adverse events (AEs) were collected for all participants from the time of signing the study-specific informed consent form until the last scheduled follow-up visit (Day 180 ±14 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/29 (0%) | 0/29 (0%) | 19/29 (65.5%) |
| 50 mg CD388 | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| 150 mg CD388 | 0/28 (0%) | 0/28 (0%) | 21/28 (75%) |
| All Arms | 0/59 (0%) | 0/59 (0%) | 41/59 (69.5%) |
| Event | Placebo | 50 mg CD388 | 150 mg CD388 | All Arms |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 12/29 | 1/2 | 15/28 | 28/59 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/29 | 1/2 | 0/28 | 1/59 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/29 | 1/2 | 0/28 | 1/59 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/29 | 1/2 | 0/28 | 1/59 |
| HeadacheNervous system disorders | 2/29 | 0/2 | 4/28 | 6/59 |
| Aspartate aminotransferase increasedInvestigations | 1/29 | 0/2 | 3/28 | 4/59 |
| Injection site painGeneral disorders | 0/29 | 0/2 | 1/28 | 1/59 |
| Oral herpesInfections and infestations | 1/29 | 0/2 | 1/28 | 2/59 |
| Bacterial vaginosisInfections and infestations | 0/29 | 0/2 | 1/28 | 1/59 |
| TonsillitisInfections and infestations | 0/29 | 0/2 | 1/28 | 1/59 |
The Safety Population included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they received.
| Age, Continuous(years) | Placebo | 50 mg CD388 | 150 mg CD388 | Total |
|---|---|---|---|---|
| Mean | 33.03 ± 8.21 | 27.50 ± 2.12 | 33.82 ± 7.86 | 33.22 ± 7.92 |
| Age, Continuous(years) | Placebo | 50 mg CD388 | 150 mg CD388 | Total |
|---|---|---|---|---|
| Median | 31.00 (22.0 to 51.0) | 27.50 (26.0 to 29.0) | 32.00 (21.0 to 51.0) | 31.00 (21.0 to 51.0) |
| Sex: Female, Male(Participants) | Placebo | 50 mg CD388 | 150 mg CD388 | Total |
|---|---|---|---|---|
| Female | 9 | 0 | 13 | 22 |
| Male | 20 | 2 | 15 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 50 mg CD388 | 150 mg CD388 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 29 | 2 | 28 | 59 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 50 mg CD388 | 150 mg CD388 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 1 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 3 | 4 |
| White | 24 | 1 | 23 | 48 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 2 |
| Region of Enrollment(participants) | Placebo | 50 mg CD388 | 150 mg CD388 | Total |
|---|---|---|---|---|
| United Kingdom | 29 | 2 | 28 | 59 |
| Weight(kilograms (kg)) | Placebo | 50 mg CD388 | 150 mg CD388 | Total |
|---|---|---|---|---|
| Mean | 76.29 ± 13.26 | 72.40 ± 2.55 | 79.68 ± 19.02 | 77.77 ± 16.04 |
| Weight(kg) | Placebo | 50 mg CD388 | 150 mg CD388 | Total |
|---|---|---|---|---|
| Median | 72.90 (54.2 to 100.8) | 72.40 (70.6 to 74.2) | 75.60 (54.2 to 112.0) | 75.20 (54.2 to 112.0) |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Jul 2023, 10 months.
Results were first posted in Sep 2024, 1 year 1 month after primary completion.
Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 10 months is above that.
Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-1406